Company intelligence / Profile preview
Immune Modulation, Inc.
- Ownership
- Private
- Development stage
- Preclinical
Overview
Immune Modulation, Inc. has developed a novel plant-based drug with anti-cancer and anti-malaria properties. The company’s mission is to bring life-saving treatments derived from nature to both developed and developing countries. There are no published clinical results yet; the company appears focused on preclinical research and product development.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Plant-based small molecules or natural products
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Immune Modulation, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immune Modulation, Inc..